Reference : WIP1 deficiency inhibits HTLV-1 Tax oncogenesis: novel therapeutic prospects for trea...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/137684
WIP1 deficiency inhibits HTLV-1 Tax oncogenesis: novel therapeutic prospects for treatment of ATL?
English
Gillet, Nicolas mailto [Université de Liège - ULiège > Chimie et bio-industries > Biologie cell. et moléc. >]
Carpentier, Alexandre mailto [Université de Liège - ULiège > Chimie et bio-industries > Biologie cell. et moléc. >]
Barez, Pierre-Yves mailto [Université de Liège - ULiège > Chimie et bio-industries > Biologie cell. et moléc. >]
Willems, Luc mailto [Université de Liège - ULiège > Chimie et bio-industries > Biologie cell. et moléc. >]
21-Dec-2012
Retrovirology
BioMed Central
9
1
115
Yes (verified by ORBi)
International
1742-4690
London
United Kingdom
[en] HTLV-1 ; Tax ; HBZ ; p53 ; Wip1 ; PPM1D ; MDM2 ; DNA damage response ; Genomic stress ; ATM ; Chk2
[en] Attenuation of p53 activity appears to be a major step in Human T-lymphotropic virus type 1 (HTLV-1) Tax transformation. However, p53 genomic mutations are late and rather infrequent events in HTLV-1 induced Adult T cell leukemia (ATL). The paper by Zane et al. shows that a mediator of p53 activity, Wild-type p53-induced phosphatase 1 (Wip1), contributes to Tax-induced oncogenesis in a mouse model. Wip1 may therefore be a novel target for therapeutic approaches.
Researchers ; Professionals ; Students ; General public
http://hdl.handle.net/2268/137684
10.1186/1742-4690-9-115
http://www.retrovirology.com/content/9/1/115

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Gillet Retrovirology 2012.pdfPublisher postprint309.77 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.